#METABOLOMICS WORKBENCH DATATRACK_ID:3888 STUDY_ID:ST002581 ANALYSIS_ID:AN004252 VERSION 1 CREATED_ON 04-27-2023 #PROJECT PR:PROJECT_TITLE MoTrPAC PR:PROJECT_SUMMARY MoTrPAC is a national research consortium designed to discover and perform PR:PROJECT_SUMMARY preliminary characterization of the range of molecular transducers (the PR:PROJECT_SUMMARY "molecular map") that underlie the effects of physical activity in humans. The PR:PROJECT_SUMMARY program's goal is to study the molecular changes that occur during and after PR:PROJECT_SUMMARY exercise and ultimately to advance the understanding of how physical activity PR:PROJECT_SUMMARY improves and preserves health. Preclinical and clinical studies will examine the PR:PROJECT_SUMMARY systemic effects of endurance and resistance exercise across a range of ages and PR:PROJECT_SUMMARY fitness levels by molecular probing of multiple tissues before and after acute PR:PROJECT_SUMMARY and chronic exercise. This program is the largest targeted NIH investment of PR:PROJECT_SUMMARY funds into the mechanisms of how physical activity improves health and prevents PR:PROJECT_SUMMARY disease. The MoTrPAC program is supported by the NIH Common Fund and is managed PR:PROJECT_SUMMARY by a trans-agency working group representing multiple NIH institutes and PR:PROJECT_SUMMARY centers, led by the NIH Office of Strategic Coordination, National Institute of PR:PROJECT_SUMMARY Arthritis and Musculoskeletal and Skin Diseases, National Institute of Diabetes PR:PROJECT_SUMMARY and Digestive and Kidney Diseases, National Institute on Aging, and National PR:PROJECT_SUMMARY Institute of Biomedical Imaging and Bioengineering. MoTrPAC Steering Committee: PR:PROJECT_SUMMARY Wendy Kohrt, Chair, Russ Tracy, Co-Chair; NIH Program Manager, Concepcion PR:PROJECT_SUMMARY Nierras. Euan Ashley and Matthew Wheeler are the PIs for the Motrpac PR:PROJECT_SUMMARY Bioinformatics / Data Coordination Center. PR:INSTITUTE MoTrPAC PR:LAST_NAME Ashley PR:FIRST_NAME Euan PR:ADDRESS Falk Building CV267, 870 Quarry Road, Stanford, California 94305 PR:EMAIL motrpac-data-deposition@lists.stanford.edu PR:PHONE (650) 725-1846 PR:DOI http://dx.doi.org/10.21228/M8V97D #STUDY ST:STUDY_TITLE MoTrPAC: Endurance exercise training study in young adult rats, Rat Plasma - ST:STUDY_TITLE Targeted Keto Acids ST:STUDY_SUMMARY The goal of the endurance exercise training study in young adult rats (internal ST:STUDY_SUMMARY code: PASS1B-06) was to perform exercise training studies in adult (6 month) ST:STUDY_SUMMARY F344 rats, and from these rats collect as many tissues as feasible in order to ST:STUDY_SUMMARY provide high quality samples for detailed analysis by chemical analysis sites. ST:STUDY_SUMMARY Tissues were collected from 10-12 rats sedentary control rats concurrent with ST:STUDY_SUMMARY the collection of the 8-week training groups. The 8-week training group and ST:STUDY_SUMMARY controls were from the same cohort and same age at euthanasia (either 8). For ST:STUDY_SUMMARY the older age group, an additional set of controls (n=5-6) were collected with ST:STUDY_SUMMARY the 1-2 week training group. Rats were either sedentary or underwent an exercise ST:STUDY_SUMMARY training program. Rats were exercised on the rodent treadmill 5 days per week ST:STUDY_SUMMARY using a progressive training protocol designed to exercise the rats at ST:STUDY_SUMMARY approximately 70% of VO2max as outlined in the Table on the next page. Training ST:STUDY_SUMMARY was performed no earlier than 10:00 am and no later than 5:00 pm over 5 ST:STUDY_SUMMARY consecutive days per week. Training was initiated with the treadmill set at 70% ST:STUDY_SUMMARY of VO2 max (see tables) and 5 degrees grade for 20 minutes. The duration of ST:STUDY_SUMMARY exercise was increased by one minute each day until day 31 of training (start of ST:STUDY_SUMMARY week 7), when a duration of 50 min was reached. Speed and grade of each training ST:STUDY_SUMMARY session increased in larger increments due to treadmill parameters. The highest ST:STUDY_SUMMARY intensity and duration of training began on day 31. This intensity was ST:STUDY_SUMMARY maintained for the final 10 days of the protocol to ensure steady state had been ST:STUDY_SUMMARY achieved. If any rats were unable to perform at least 4 days of training per ST:STUDY_SUMMARY week they were removed from the study and euthanized. It is important to note ST:STUDY_SUMMARY that the starting treadmill speed varied depending on the sex and age of the ST:STUDY_SUMMARY rat. The initial and maximum speeds were based on VO2max measurements obtained ST:STUDY_SUMMARY during the pre-training testing of the compliant rats. Rats assigned to the ST:STUDY_SUMMARY control group followed a schedule similar to the training group. They were ST:STUDY_SUMMARY placed in one lane on the treadmill for 15 minutes/day, 5 days per week. The ST:STUDY_SUMMARY treadmill was set at 0 m/min at an incline that corresponded to the incline ST:STUDY_SUMMARY being used by the training group. ST:INSTITUTE Duke University ST:DEPARTMENT Duke Molecular Physiology Institute ST:LABORATORY Metabolomics Core Laboratory ST:LAST_NAME Newgard ST:FIRST_NAME Christopher ST:ADDRESS 300 N Duke St, Durham, NC 27701 ST:EMAIL chris.newgard@duke.edu ST:PHONE (919) 668-6059 ST:SUBMIT_DATE 2023-04-25 #SUBJECT SU:SUBJECT_TYPE Mammal SU:SUBJECT_SPECIES Rattus norvegicus SU:TAXONOMY_ID 10116 #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data SUBJECT_SAMPLE_FACTORS 1628FB23-6F66-47D4-8D82-63C87726F0FD 90245013108 Group:Control | Timepoint:8 weeks of training or control time | Sex:Female raw_file=Motorpac_PASS1B_Plasma_072720_a036.zip SUBJECT_SAMPLE_FACTORS 69FD4884-786D-4F2A-97B1-6174FBD25D60 90248013108 Group:Control | Timepoint:8 weeks of training or control time | Sex:Female raw_file=Motorpac_PASS1B_Plasma_072720_a052.zip SUBJECT_SAMPLE_FACTORS 07AF7369-F082-4CA7-99D5-D973F4A162C9 90252013108 Group:Control | Timepoint:8 weeks of training or control time | Sex:Female raw_file=Motorpac_PASS1B_Plasma_072720_a055.zip SUBJECT_SAMPLE_FACTORS F9BEE1FA-E2DB-4BE4-A79C-99D585D6FD17 90265013108 Group:Control | Timepoint:8 weeks of training or control time | Sex:Female raw_file=Motorpac_PASS1B_Plasma_072720_a034.zip SUBJECT_SAMPLE_FACTORS A77AC89A-1D9E-4516-9DA4-2BE99C8126EF 90266013108 Group:Control | Timepoint:8 weeks of training or control time | Sex:Female raw_file=Motorpac_PASS1B_Plasma_072720_a050.zip SUBJECT_SAMPLE_FACTORS BC49E4EF-E2FE-4269-BAF0-461F768BD95D 90217013108 Group:Control | Timepoint:8 weeks of training or control time | Sex:Male raw_file=Motorpac_PASS1B_Plasma_072720_a031.zip SUBJECT_SAMPLE_FACTORS 0559B193-BED3-4170-B045-10A2B6441CB6 90229013108 Group:Control | Timepoint:8 weeks of training or control time | Sex:Male raw_file=Motorpac_PASS1B_Plasma_072720_a067.zip SUBJECT_SAMPLE_FACTORS 90CFE5A4-76FE-4458-A2B1-A66F0B60118E 90232013108 Group:Control | Timepoint:8 weeks of training or control time | Sex:Male raw_file=Motorpac_PASS1B_Plasma_072720_a060.zip SUBJECT_SAMPLE_FACTORS F0D83B29-8EFA-4CDE-B1AA-2358AC220ECF 90237013108 Group:Control | Timepoint:8 weeks of training or control time | Sex:Male raw_file=Motorpac_PASS1B_Plasma_072720_a054.zip SUBJECT_SAMPLE_FACTORS FCE9ABE6-B60B-4934-BAE5-56AF8B11ECEC 90239013108 Group:Control | Timepoint:8 weeks of training or control time | Sex:Male raw_file=Motorpac_PASS1B_Plasma_072720_a056.zip SUBJECT_SAMPLE_FACTORS - 80014813102_2 Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- raw_file=Motorpac_PASS1B_Plasma_072720_a044.zip SUBJECT_SAMPLE_FACTORS - 80014813102_3 Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- raw_file=Motorpac_PASS1B_Plasma_072720_a063.zip SUBJECT_SAMPLE_FACTORS - 80014813102_4 Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- raw_file=Motorpac_PASS1B_Plasma_072720_a081.zip SUBJECT_SAMPLE_FACTORS - 80015823102_1 Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- raw_file=Motorpac_PASS1B_Plasma_072720_a026.zip SUBJECT_SAMPLE_FACTORS - 80015823102_2 Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- raw_file=Motorpac_PASS1B_Plasma_072720_a045.zip SUBJECT_SAMPLE_FACTORS - 80015823102_3 Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- raw_file=Motorpac_PASS1B_Plasma_072720_a064.zip SUBJECT_SAMPLE_FACTORS - 80015823102_4 Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- raw_file=Motorpac_PASS1B_Plasma_072720_a082.zip SUBJECT_SAMPLE_FACTORS - 80014813102_1 Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- | Tissue:- raw_file=Motorpac_PASS1B_Plasma_072720_a025.zip SUBJECT_SAMPLE_FACTORS B73AB139-7210-4498-9CCF-E1DBE6EBA71C 90559013108 Group:Training | Timepoint:1 week of training or control time | Sex:Female raw_file=Motorpac_PASS1B_Plasma_072720_a032.zip SUBJECT_SAMPLE_FACTORS EA5C8932-9325-4DA5-96BB-50CD49CEDD10 90560013108 Group:Training | Timepoint:1 week of training or control time | Sex:Female raw_file=Motorpac_PASS1B_Plasma_072720_a048.zip SUBJECT_SAMPLE_FACTORS 0645F621-878C-4C9B-84A6-58862BAA17D9 90564013108 Group:Training | Timepoint:1 week of training or control time | Sex:Female raw_file=Motorpac_PASS1B_Plasma_072720_a046.zip SUBJECT_SAMPLE_FACTORS 68083256-8DAA-4185-B446-0CAF600474B5 90567013108 Group:Training | Timepoint:1 week of training or control time | Sex:Female raw_file=Motorpac_PASS1B_Plasma_072720_a051.zip SUBJECT_SAMPLE_FACTORS 6A013AA1-4D1E-4B75-B691-6BA22D928E51 90571013108 Group:Training | Timepoint:1 week of training or control time | Sex:Female raw_file=Motorpac_PASS1B_Plasma_072720_a057.zip SUBJECT_SAMPLE_FACTORS 6D680EA2-C62B-4A35-8B6E-2ED6A79CB017 90421013108 Group:Training | Timepoint:1 week of training or control time | Sex:Male raw_file=Motorpac_PASS1B_Plasma_072720_a040.zip SUBJECT_SAMPLE_FACTORS 53F914B0-FD4F-4340-84A6-48341EAB3798 90422013108 Group:Training | Timepoint:1 week of training or control time | Sex:Male raw_file=Motorpac_PASS1B_Plasma_072720_a041.zip SUBJECT_SAMPLE_FACTORS D350D633-8D95-4783-99F2-BB8294D2EC32 90423013108 Group:Training | Timepoint:1 week of training or control time | Sex:Male raw_file=Motorpac_PASS1B_Plasma_072720_a049.zip SUBJECT_SAMPLE_FACTORS 0DBFEB04-1B58-43CF-BAFD-9AA9915B67F6 90426013108 Group:Training | Timepoint:1 week of training or control time | Sex:Male raw_file=Motorpac_PASS1B_Plasma_072720_a058.zip SUBJECT_SAMPLE_FACTORS 10E282EB-1DBA-406E-BD5D-81027083A01D 90430013108 Group:Training | Timepoint:1 week of training or control time | Sex:Male raw_file=Motorpac_PASS1B_Plasma_072720_a028.zip SUBJECT_SAMPLE_FACTORS B137E81D-A9DE-4E3A-8E2B-AD6C22920B7E 90576013108 Group:Training | Timepoint:2 weeks of training | Sex:Female raw_file=Motorpac_PASS1B_Plasma_072720_a033.zip SUBJECT_SAMPLE_FACTORS DC8B35E8-4AA8-4829-8569-F223D069620C 90578013108 Group:Training | Timepoint:2 weeks of training | Sex:Female raw_file=Motorpac_PASS1B_Plasma_072720_a027.zip SUBJECT_SAMPLE_FACTORS 8904857C-2073-4BBA-AC7C-1EC239E5BFF7 90581013108 Group:Training | Timepoint:2 weeks of training | Sex:Female raw_file=Motorpac_PASS1B_Plasma_072720_a076.zip SUBJECT_SAMPLE_FACTORS 1F9BD644-303F-43E7-94BE-FF6654306F5E 90585013108 Group:Training | Timepoint:2 weeks of training | Sex:Female raw_file=Motorpac_PASS1B_Plasma_072720_a073.zip SUBJECT_SAMPLE_FACTORS 0409BED3-F9FE-4C06-9920-74F5E5CA04A3 90587013108 Group:Training | Timepoint:2 weeks of training | Sex:Female raw_file=Motorpac_PASS1B_Plasma_072720_a080.zip SUBJECT_SAMPLE_FACTORS 4E974304-21EB-42E8-A729-A7FB6B406E64 90439013108 Group:Training | Timepoint:2 weeks of training | Sex:Male raw_file=Motorpac_PASS1B_Plasma_072720_a078.zip SUBJECT_SAMPLE_FACTORS 6527EC12-E7EB-4F17-BF0A-0AC7CD1819A0 90441013108 Group:Training | Timepoint:2 weeks of training | Sex:Male raw_file=Motorpac_PASS1B_Plasma_072720_a069.zip SUBJECT_SAMPLE_FACTORS AEB1611A-F29E-43F8-B9F3-A2BC4F9EB504 90444013108 Group:Training | Timepoint:2 weeks of training | Sex:Male raw_file=Motorpac_PASS1B_Plasma_072720_a038.zip SUBJECT_SAMPLE_FACTORS FDA87A8D-3634-4C42-9A1A-0EA03B58BB01 90449013108 Group:Training | Timepoint:2 weeks of training | Sex:Male raw_file=Motorpac_PASS1B_Plasma_072720_a035.zip SUBJECT_SAMPLE_FACTORS CDCFA3F1-07ED-4737-A36D-15EFEC325AA5 90450013108 Group:Training | Timepoint:2 weeks of training | Sex:Male raw_file=Motorpac_PASS1B_Plasma_072720_a037.zip SUBJECT_SAMPLE_FACTORS 2E37478F-525F-4E5E-A882-EE75FD0CFB29 90406013108 Group:Training | Timepoint:4 weeks of training | Sex:Female raw_file=Motorpac_PASS1B_Plasma_072720_a068.zip SUBJECT_SAMPLE_FACTORS A9CE3E3D-31A0-4443-8A7F-8FD831D79248 90410013108 Group:Training | Timepoint:4 weeks of training | Sex:Female raw_file=Motorpac_PASS1B_Plasma_072720_a072.zip SUBJECT_SAMPLE_FACTORS 3D5BC47C-BB3D-45A2-8DB8-D7ADCD51997C 90412013108 Group:Training | Timepoint:4 weeks of training | Sex:Female raw_file=Motorpac_PASS1B_Plasma_072720_a079.zip SUBJECT_SAMPLE_FACTORS 89D6F615-D17C-4EB9-88EB-A602940FF179 90416013108 Group:Training | Timepoint:4 weeks of training | Sex:Female raw_file=Motorpac_PASS1B_Plasma_072720_a061.zip SUBJECT_SAMPLE_FACTORS FE012DC0-AF32-4C70-A4D4-F042B8BC4EC6 90420013108 Group:Training | Timepoint:4 weeks of training | Sex:Female raw_file=Motorpac_PASS1B_Plasma_072720_a053.zip SUBJECT_SAMPLE_FACTORS 22D700B9-EDD0-4BC8-8155-EB9C39417F81 90280013108 Group:Training | Timepoint:4 weeks of training | Sex:Male raw_file=Motorpac_PASS1B_Plasma_072720_a070.zip SUBJECT_SAMPLE_FACTORS 1CA4210C-3CE6-4A5A-996B-673EBDEB3B81 90281013108 Group:Training | Timepoint:4 weeks of training | Sex:Male raw_file=Motorpac_PASS1B_Plasma_072720_a062.zip SUBJECT_SAMPLE_FACTORS 9F3E1040-D409-421E-B635-2572DC20ED89 90283013108 Group:Training | Timepoint:4 weeks of training | Sex:Male raw_file=Motorpac_PASS1B_Plasma_072720_a042.zip SUBJECT_SAMPLE_FACTORS 569A9229-04E8-414A-A195-FE9E8F1B66AB 90289013108 Group:Training | Timepoint:4 weeks of training | Sex:Male raw_file=Motorpac_PASS1B_Plasma_072720_a043.zip SUBJECT_SAMPLE_FACTORS E4271AF1-899A-4A65-9D8D-BF18CEE3F1CF 90292013108 Group:Training | Timepoint:4 weeks of training | Sex:Male raw_file=Motorpac_PASS1B_Plasma_072720_a029.zip SUBJECT_SAMPLE_FACTORS 0D5071F5-D166-4CF1-BE8B-EB4DF6E04C0E 90251013108 Group:Training | Timepoint:8 weeks of training or control time | Sex:Female raw_file=Motorpac_PASS1B_Plasma_072720_a030.zip SUBJECT_SAMPLE_FACTORS 2479BEE5-2A38-4D09-B15B-B1715F561A9F 90254013108 Group:Training | Timepoint:8 weeks of training or control time | Sex:Female raw_file=Motorpac_PASS1B_Plasma_072720_a059.zip SUBJECT_SAMPLE_FACTORS 0A4A7935-3AF4-463F-84E3-DCF07671509D 90258013108 Group:Training | Timepoint:8 weeks of training or control time | Sex:Female raw_file=Motorpac_PASS1B_Plasma_072720_a039.zip SUBJECT_SAMPLE_FACTORS 04C84D7E-FC8C-422F-AE4B-CAFADB63407B 90259013108 Group:Training | Timepoint:8 weeks of training or control time | Sex:Female raw_file=Motorpac_PASS1B_Plasma_072720_a075.zip SUBJECT_SAMPLE_FACTORS 2B969165-1A52-43AA-8FD9-39AFA62F094F 90267013108 Group:Training | Timepoint:8 weeks of training or control time | Sex:Female raw_file=Motorpac_PASS1B_Plasma_072720_a071.zip SUBJECT_SAMPLE_FACTORS 0BD282C7-7832-4581-9089-08A32D557034 90218013108 Group:Training | Timepoint:8 weeks of training or control time | Sex:Male raw_file=Motorpac_PASS1B_Plasma_072720_a066.zip SUBJECT_SAMPLE_FACTORS 955498F4-70A0-4D50-A2BA-619A8FED8FEF 90222013108 Group:Training | Timepoint:8 weeks of training or control time | Sex:Male raw_file=Motorpac_PASS1B_Plasma_072720_a047.zip SUBJECT_SAMPLE_FACTORS CFE06932-9314-4BCC-B2D9-73883D5FCDFB 90223013108 Group:Training | Timepoint:8 weeks of training or control time | Sex:Male raw_file=Motorpac_PASS1B_Plasma_072720_a074.zip SUBJECT_SAMPLE_FACTORS 3719CB62-B551-49BE-94A0-E51DFE13D30D 90225013108 Group:Training | Timepoint:8 weeks of training or control time | Sex:Male raw_file=Motorpac_PASS1B_Plasma_072720_a077.zip SUBJECT_SAMPLE_FACTORS F65955CE-E49F-48C7-B861-02A2FDF6F9B8 90227013108 Group:Training | Timepoint:8 weeks of training or control time | Sex:Male raw_file=Motorpac_PASS1B_Plasma_072720_a065.zip #COLLECTION CO:SAMPLE_TYPE Plasma #TREATMENT TR:TREATMENT_SUMMARY - #SAMPLEPREP SP:SAMPLEPREP_SUMMARY 10 µl of plasma or 300 µl of tissue homogenate prepared at 100 mg/ml in 3M SP:SAMPLEPREP_SUMMARY perchloric acid containing isotopically labeled internal standards KIC-d3, SP:SAMPLEPREP_SUMMARY KIV-5C13, (Cambridge Isotope Laboratories), and KMV-d8 (Toronto Research SP:SAMPLEPREP_SUMMARY Chemicals) are precipitated with 150 µl of 3M PCA. 200 µl of 25 M SP:SAMPLEPREP_SUMMARY o-phenylenediamine (OPD) in 3M HCl is added to the supernatants and the samples SP:SAMPLEPREP_SUMMARY are incubated at 80oC for 20 minutes. Keto acids are extracted with ethyl SP:SAMPLEPREP_SUMMARY acetate. The extracts are dried under nitrogen and reconstituted in 200 mM SP:SAMPLEPREP_SUMMARY ammonium acetate. #CHROMATOGRAPHY CH:CHROMATOGRAPHY_SUMMARY The analytical column is used at 30°C. 10 µl of the sample are injected onto CH:CHROMATOGRAPHY_SUMMARY the column and eluted at a flow rate of 0.4 ml/min. The gradient begins with 45% CH:CHROMATOGRAPHY_SUMMARY eluent A (5 mM ammonium acetate in water) and is then programmed as follows: 0 CH:CHROMATOGRAPHY_SUMMARY to 2 min – gradient to 55% eluent B (methanol); 2 to 2.5 min - gradient to 95% CH:CHROMATOGRAPHY_SUMMARY eluent B; 2.5 to 3.2 min - hold at 95% eluent B, return to 45% A, and CH:CHROMATOGRAPHY_SUMMARY re-equilibrate the column at initial conditions for 1 minute. CH:INSTRUMENT_NAME Waters Acquity UPLC CH:COLUMN_NAME Waters Acquity UPLC BEH C18 Column, 1.7 µm, 2.1 × 50 mm CH:COLUMN_TEMPERATURE 30C CH:FLOW_GRADIENT 45% A and 55% B for 2 minutes, followed by a linear gradient to 95% B from 2 to CH:FLOW_GRADIENT 2.5 minutes, held at 95% B for 0.7 minutes, returned to 45% A, and finally the CH:FLOW_GRADIENT column was re-equilibrated at initial conditions for 1 minute. The total run CH:FLOW_GRADIENT time was 4.7 minutes. CH:FLOW_RATE 0.4 ml/min CH:SOLVENT_A 100% water; 5 mM ammonium acetate CH:SOLVENT_B 100% methanol CH:CHROMATOGRAPHY_TYPE Reversed phase #ANALYSIS AN:ANALYSIS_TYPE MS #MS MS:INSTRUMENT_NAME Waters Xevo TQ-S MS:INSTRUMENT_TYPE Triple quadrupole MS:MS_TYPE ESI MS:MS_COMMENTS Mass transitions of m/z 203 -> 161 (ketoleucine or KIC), 206 -> 161 MS:MS_COMMENTS (KIC-d3), 189 -> 174 (ketoisovalerate or KIV), 194 -> 178 (KIV-5C13), 203 MS:MS_COMMENTS -> 174 (3-methyl-2-oxovalerate or KMV), and 211 -> 177 (KMV-d8) are MS:MS_COMMENTS monitored in a positive ion electrospray ionization mode. MS:ION_MODE POSITIVE #MS_METABOLITE_DATA MS_METABOLITE_DATA:UNITS micromole/L MS_METABOLITE_DATA_START Samples 90245013108 90248013108 90252013108 90265013108 90266013108 90217013108 90229013108 90232013108 90237013108 90239013108 80014813102_2 80014813102_3 80014813102_4 80015823102_1 80015823102_2 80015823102_3 80015823102_4 80014813102_1 90559013108 90560013108 90564013108 90567013108 90571013108 90421013108 90422013108 90423013108 90426013108 90430013108 90576013108 90578013108 90581013108 90585013108 90587013108 90439013108 90441013108 90444013108 90449013108 90450013108 90406013108 90410013108 90412013108 90416013108 90420013108 90280013108 90281013108 90283013108 90289013108 90292013108 90251013108 90254013108 90258013108 90259013108 90267013108 90218013108 90222013108 90223013108 90225013108 90227013108 Factors Group:Control | Timepoint:8 weeks of training or control time | Sex:Female Group:Control | Timepoint:8 weeks of training or control time | Sex:Female Group:Control | Timepoint:8 weeks of training or control time | Sex:Female Group:Control | Timepoint:8 weeks of training or control time | Sex:Female Group:Control | Timepoint:8 weeks of training or control time | Sex:Female Group:Control | Timepoint:8 weeks of training or control time | Sex:Male Group:Control | Timepoint:8 weeks of training or control time | Sex:Male Group:Control | Timepoint:8 weeks of training or control time | Sex:Male Group:Control | Timepoint:8 weeks of training or control time | Sex:Male Group:Control | Timepoint:8 weeks of training or control time | Sex:Male Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- | Tissue:- Group:Training | Timepoint:1 week of training or control time | Sex:Female Group:Training | Timepoint:1 week of training or control time | Sex:Female Group:Training | Timepoint:1 week of training or control time | Sex:Female Group:Training | Timepoint:1 week of training or control time | Sex:Female Group:Training | Timepoint:1 week of training or control time | Sex:Female Group:Training | Timepoint:1 week of training or control time | Sex:Male Group:Training | Timepoint:1 week of training or control time | Sex:Male Group:Training | Timepoint:1 week of training or control time | Sex:Male Group:Training | Timepoint:1 week of training or control time | Sex:Male Group:Training | Timepoint:1 week of training or control time | Sex:Male Group:Training | Timepoint:2 weeks of training | Sex:Female Group:Training | Timepoint:2 weeks of training | Sex:Female Group:Training | Timepoint:2 weeks of training | Sex:Female Group:Training | Timepoint:2 weeks of training | Sex:Female Group:Training | Timepoint:2 weeks of training | Sex:Female Group:Training | Timepoint:2 weeks of training | Sex:Male Group:Training | Timepoint:2 weeks of training | Sex:Male Group:Training | Timepoint:2 weeks of training | Sex:Male Group:Training | Timepoint:2 weeks of training | Sex:Male Group:Training | Timepoint:2 weeks of training | Sex:Male Group:Training | Timepoint:4 weeks of training | Sex:Female Group:Training | Timepoint:4 weeks of training | Sex:Female Group:Training | Timepoint:4 weeks of training | Sex:Female Group:Training | Timepoint:4 weeks of training | Sex:Female Group:Training | Timepoint:4 weeks of training | Sex:Female Group:Training | Timepoint:4 weeks of training | Sex:Male Group:Training | Timepoint:4 weeks of training | Sex:Male Group:Training | Timepoint:4 weeks of training | Sex:Male Group:Training | Timepoint:4 weeks of training | Sex:Male Group:Training | Timepoint:4 weeks of training | Sex:Male Group:Training | Timepoint:8 weeks of training or control time | Sex:Female Group:Training | Timepoint:8 weeks of training or control time | Sex:Female Group:Training | Timepoint:8 weeks of training or control time | Sex:Female Group:Training | Timepoint:8 weeks of training or control time | Sex:Female Group:Training | Timepoint:8 weeks of training or control time | Sex:Female Group:Training | Timepoint:8 weeks of training or control time | Sex:Male Group:Training | Timepoint:8 weeks of training or control time | Sex:Male Group:Training | Timepoint:8 weeks of training or control time | Sex:Male Group:Training | Timepoint:8 weeks of training or control time | Sex:Male Group:Training | Timepoint:8 weeks of training or control time | Sex:Male 3-methyl-2-oxovalerate 47.9877 30.7237 38.4465 22.8709 32.6713 26.1624 39.9520 32.4027 32.0705 29.4407 59.4258 59.6919 58.8789 28.2759 29.1376 29.0668 28.9817 57.1108 31.3411 24.0863 44.3011 35.6961 38.6928 28.3027 29.1806 30.3358 29.2975 28.2819 40.5370 36.0820 42.5766 38.4134 50.8861 29.8050 25.3717 29.2692 34.8043 26.1661 37.6526 29.5003 32.2712 35.3197 26.7028 31.9058 26.9391 30.4359 29.9439 26.3231 35.7338 30.8314 30.7681 30.4837 32.1862 32.7347 39.4016 34.0117 32.8843 36.1293 ketoisovalerate 20.0047 12.5270 14.1134 9.4829 12.2136 10.2692 14.9473 11.6475 11.5358 11.1655 25.5687 25.0802 25.0636 11.5976 11.6233 11.5088 11.7162 25.6454 12.5202 10.9548 14.0335 12.6927 13.3893 10.7848 11.3894 11.5680 10.5859 11.3842 15.7036 13.5075 14.3841 12.8468 15.2607 10.9972 10.4130 12.0482 14.8217 9.5201 12.1960 11.6828 12.2725 12.1894 10.8494 12.3494 10.2996 12.0590 10.8590 9.4535 12.7361 12.4611 12.0588 10.8660 11.8830 11.4061 13.5145 12.3726 11.8278 13.9446 ketoleucine 52.1608 29.7906 33.3994 21.1400 29.6105 23.4150 36.6947 26.7697 29.2932 26.0023 55.8513 54.7763 54.9988 27.0669 27.5974 27.2228 27.1804 55.1562 33.3787 25.5816 34.5071 32.4853 33.2289 25.6970 26.1968 27.2616 25.4974 26.9902 40.2328 33.9259 35.4678 33.1087 40.0043 25.5909 22.2271 26.7042 32.6477 21.5085 29.9468 27.7243 31.9298 31.7017 25.3641 29.7801 24.5472 28.1329 25.9878 22.1798 30.0820 28.5936 29.4169 28.4064 29.6354 27.3323 32.4169 29.9031 29.9468 34.3756 MS_METABOLITE_DATA_END #METABOLITES METABOLITES_START metabolite_name pubchem_id inchi_key kegg_id other_id other_id_type ri ri_type moverz_quant 3-methyl-2-oxovalerate ketoisovalerate ketoleucine METABOLITES_END #END